聚氨酯微颗粒作为贝伐单抗载体的开发和体外评价:早产儿视网膜病变的替代治疗。

R. Albulescu, F. Borcan, C. Paul, I. Velea, M. Puiu
{"title":"聚氨酯微颗粒作为贝伐单抗载体的开发和体外评价:早产儿视网膜病变的替代治疗。","authors":"R. Albulescu, F. Borcan, C. Paul, I. Velea, M. Puiu","doi":"10.3329/ICPJ.V3I6.18759","DOIUrl":null,"url":null,"abstract":"Retinopathy of prematurity (ROP) is known as an abnormal development of the blood capillaries from the eyes’ retina, and it is met to those infants that were born too early (premature) as its name suggests. Bevacizumab or Avastin belongs to the class of monoclonal antibodies and it is a possible treatment for those patients who have been diagnosed with a recurrent malignant glioma or other cancers due to its behavior to bind selectively to vascular endothelial growth factor (VEGF). In this study, eye drops based on a polyurethane carrier used for bevacizumab were obtained and the degradation of this carrier was studied for three weeks in two different media: simulated body fluid (SBF) and phosphate buffered saline (PBS); the influence of ultrasounds on the degradation of polyurethane carrier was also evaluated. The obtained results suggest that the polyurethane carrier presents a very slow degradation which is beneficial for drugs which require low release rates and on the other hand, the concentrations of the degradation products remain at a low level. DOI:  http://dx.doi.org/10.3329/icpj.v3i6.18759 International Current Pharmaceutical Journal, May 2014, 3(6): 275-279","PeriodicalId":13811,"journal":{"name":"International Current Pharmaceutical Journal","volume":"26 1","pages":"275-279"},"PeriodicalIF":0.0000,"publicationDate":"2014-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity.\",\"authors\":\"R. Albulescu, F. Borcan, C. Paul, I. Velea, M. Puiu\",\"doi\":\"10.3329/ICPJ.V3I6.18759\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Retinopathy of prematurity (ROP) is known as an abnormal development of the blood capillaries from the eyes’ retina, and it is met to those infants that were born too early (premature) as its name suggests. Bevacizumab or Avastin belongs to the class of monoclonal antibodies and it is a possible treatment for those patients who have been diagnosed with a recurrent malignant glioma or other cancers due to its behavior to bind selectively to vascular endothelial growth factor (VEGF). In this study, eye drops based on a polyurethane carrier used for bevacizumab were obtained and the degradation of this carrier was studied for three weeks in two different media: simulated body fluid (SBF) and phosphate buffered saline (PBS); the influence of ultrasounds on the degradation of polyurethane carrier was also evaluated. The obtained results suggest that the polyurethane carrier presents a very slow degradation which is beneficial for drugs which require low release rates and on the other hand, the concentrations of the degradation products remain at a low level. DOI:  http://dx.doi.org/10.3329/icpj.v3i6.18759 International Current Pharmaceutical Journal, May 2014, 3(6): 275-279\",\"PeriodicalId\":13811,\"journal\":{\"name\":\"International Current Pharmaceutical Journal\",\"volume\":\"26 1\",\"pages\":\"275-279\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Current Pharmaceutical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3329/ICPJ.V3I6.18759\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Current Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/ICPJ.V3I6.18759","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

早产儿视网膜病变(ROP)是一种眼睛视网膜毛细血管的异常发育,顾名思义,它会发生在那些出生过早(早产)的婴儿身上。贝伐单抗或阿瓦斯汀属于单克隆抗体类别,由于其选择性结合血管内皮生长因子(VEGF)的行为,它可能用于那些被诊断为复发性恶性胶质瘤或其他癌症的患者。在这项研究中,研究人员获得了用于贝伐单抗的基于聚氨酯载体的滴眼液,并研究了该载体在两种不同介质中三周的降解情况:模拟体液(SBF)和磷酸盐缓冲盐水(PBS);研究了超声波对聚氨酯载体降解的影响。结果表明,聚氨酯载体的降解非常缓慢,这有利于低释放率的药物的降解,另一方面,降解产物的浓度保持在较低的水平。DOI: http://dx.doi.org/10.3329/icpj.v3i6.18759国际现代医药杂志,2014年5月,3(6):275-279
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity.
Retinopathy of prematurity (ROP) is known as an abnormal development of the blood capillaries from the eyes’ retina, and it is met to those infants that were born too early (premature) as its name suggests. Bevacizumab or Avastin belongs to the class of monoclonal antibodies and it is a possible treatment for those patients who have been diagnosed with a recurrent malignant glioma or other cancers due to its behavior to bind selectively to vascular endothelial growth factor (VEGF). In this study, eye drops based on a polyurethane carrier used for bevacizumab were obtained and the degradation of this carrier was studied for three weeks in two different media: simulated body fluid (SBF) and phosphate buffered saline (PBS); the influence of ultrasounds on the degradation of polyurethane carrier was also evaluated. The obtained results suggest that the polyurethane carrier presents a very slow degradation which is beneficial for drugs which require low release rates and on the other hand, the concentrations of the degradation products remain at a low level. DOI:  http://dx.doi.org/10.3329/icpj.v3i6.18759 International Current Pharmaceutical Journal, May 2014, 3(6): 275-279
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信